Verve stock price is benefiting from overall sector optimism, especially after comparable gene-editing firms posted double-digit gains. Short interest is declining, which may signal an easing of bearish sentiment in the stock. Following the upgrade, the current consensus from Verve Therapeutics' ten analysts is for revenues of US$21m in 2024 which - if met - would reflect a huge 28% increase on its sales over the past 12 months. Per-share losses are expected to see a sharp uptick, reaching US$2.70. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$13m and losses of US$2.93 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023, after Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year. REUTERS/Mike Blake/File Photo Purchase Licensing Rights , opens new tab Options flow indicates some bullish positioning, with traders betting on positive Phase 1 trial updates within Q